616700bf03ec3707470d8a9b efficacy-of-cenobamate-for-uncontrolled-focal-seizures-post-hoc-analysis-of-a-phase-3-multicenter-open-label-study 2021-10-13T15:53:53.412Z 5e283dc83b5e750642253ad8 793637c7-9615-42b1-905c-4827a6fab04c mas_evidence_types:Other%20primary%20research Primary research Post-hoc analysis (n=255) found 71.7% of patients had a 50% reduction in seizures and 36.3% had 100% seizure reduction for ≥12 consecutive months during the study. Fatigue, dizziness, somnolence were the most commonly reported adverse effects. <p>This is one of two analyses of data from 10 US study sites from an open-label phase 3 study of adjunctive cenobamate published in Epilepsia. The other analysis reviewing use of concomitant antiseizure medicines found 81% had a 50% or more reduction in seizures, with 12% being seizure free, after a median of 30.2 months treatment and 24.6% of patients had discontinued one or more concomitant antiseizure medications completely.</p> <p>&nbsp;</p> <p>Cenobamate is a sodium channel blocker, with a different binding site to classical sodium channel blocking drugs; it enhances GABAergic transmission by increasing presynaptic GABA release.&nbsp; It is licensed in the UK, but has not yet been launched.</p> https://www.medicinesresources.nhs.uk/efficacy-of-cenobamate-for-uncontrolled-focal-seizures-post-hoc-analysis-of-a-phase-3-multicenter-open-label-study.html <p><a href="https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17092">Other post hoc analysis</a></p> https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17091 2021-10-11T00:00:00Z 2021-10-13T15:52:31.554Z